Infliximab: a review of its use in the treatment of Crohn's disease.
Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was developed in the treatment of rheumatologic diseases its effects on Crohn's disease have revolutionized the management of this chronic illness. Infliximab has effects on both immune and epithelial ce...
| Publicado en: | Clinical Medicine: Therapeutics no. 1; pp. 1351 - 1366 |
|---|---|
| Autores principales: | , , |
| Formato: | review Journal Article |
| Publicado: |
Sage Publications Inc.
2009
|
| Acceso en línea: | Ver este registro en EBSCOhost |